
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Autism : Clinical pears for primary care Puzzler : Toddler with vomiting after head injury Dermcase : Every day is a bad hair day Female athlete triad in adolescents






